Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

Inari Medical, Inc. (NASDAQ:NARI ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Caroline Corner - IR Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Adam Maeder - Piper Sandler William Plovanic - Canaccord Marie Thibault - BTIG Richard Newitter - Truist Securities Mike Sarcone - Jeffries Operator Good afternoon, and welcome to the Inari Medical Inc.'s First Quarter 2023 Earnings Call. All participants will be in listen-only mode.

Inari Medical, Inc. (NARI) Q1 2023 Earnings Call Transcript

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its first quarter ended March 31, 2023.

Inari Medical Reports First Quarter 2023 Financial Results

IRVINE, Calif., May 02, 2023 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the Bank of America 2023 Healthcare Conference on Tuesday, May 9, 2023 at 3:00 p.m. Pacific Time at the Encore Hotel in Las Vegas.

Inari Medical to Present at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce First Quarter 2023 Financial Results

Inari Medical released positive news regarding its FlowTriever system to prevent pulmonary emboli. The company saw revenue rise by 38% in 2022.

Why Shares of Inari Medical Rose This Week

IRVINE, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced positive results from the FLAME study in high-risk/massive pulmonary embolism (“PE”). The data was presented during the Late-Breaking Clinical and Investigative Horizons session at the 2023 ACC (American College of Cardiology) conference on March 5th by national Principal Investigator (PI) Mitchell Silver, DO, FACC, FVSM, RPVI, an interventional cardiologist and vascular medicine specialist at OhioHealth Riverside Methodist Hospital.

FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System

Inari Medical has solid top-line growth with expansion in core and new product lines. It continues to focus on reinvestment into future growth, especially in international markets.

Inari Medical: Reinvesting Heavily Into Growing International Markets

Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical (NARI) Q4 Earnings Beat, Revenues Rise Y/Y

Inari Medical, Inc. (NASDAQ:NARI ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Caroline Corner - IR Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Conference Call Participants Travis Steed - Bank of America Cecilia Furlong - Morgan Stanley Larry Biegelsen - Wells Fargo Adam Maeder - Piper Sandler Marie Thibault - BTIG Bill Plovanic - Canaccord Mike Sarcone - Jefferies Richard Newitter - Truist Operator Good afternoon, and welcome to the Inari Medical Fourth Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Inari Medical, Inc. (NARI) Q4 2022 Earnings Call Transcript

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 35.29% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Reports Q4 Loss, Tops Revenue Estimates

IRVINE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its fourth quarter and full year ended December 31, 2022.

Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results

Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Inari Medical, Inc. (NARI) Soars 6.3%: Is Further Upside Left in the Stock?

Amazon

Inmode Ltd

Find out why the investment bankers who follow these stocks think they can soar in the near term.

3 Magnificent Growth Stocks With 38% to 64% Upside Potential, According to Wall Street

IRVINE, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and full year 2022 financial results on Monday, February 27, 2023. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14, 2023.

Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Shockwave Medical

These stocks are all down by at least 42% from their all-time highs despite impressive performances from their underlying businesses.

3 Beaten-Down Growth Stocks That I'm Loading Up On in 2023

Inari Medical's (NARI) revenue growth in the fourth quarter is likely to have been boosted by continued demand for its products, market expansion and new launches.

Inari Medical (NARI) Reports Solid Preliminary Q4 Revenues

Inari Medical, Inc. (NARI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Inari Medical, Inc. (NARI): Can Its 5.6% Jump Turn into More Strength?

UiPath

These companies are reporting financial results that aren't being reflected in their stock market performances.

3 Remarkable Growth Stocks That Could Climb 39% to 46%, According to Wall Street

IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 2:15PM Pacific Time.

Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference

Doximity

These relatively reliable healthcare businesses are performing much better than their beaten-down stock prices would suggest.

2 Top Growth Stocks Down 42.6% and 68.5% to Buy Before They Rebound in 2023

Management raised FY22 revenue guidance to $373–$375mm, from a previous $360-$370mm. This followed a strong quarter with procedural growth across the portfolio.

Inari Medical: Retain Buy, No Change To Targets Despite Flat Price Action

Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.

Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y

Inari Medical, Inc. (NASDAQ:NARI ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Caroline Corner – Investor Relations Bill Hoffman – President and Chief Executive Officer Drew Hykes – Chief Operating Officer Mitch Hill – Chief Financial Officer Tom Tu – Chief Medical Officer Conference Call Participants Travis Steed – Bank of America Cecilia Furlong – Morgan Stanley Larry Biegelsen – Wells Fargo Marie Thibault – BTIG Bill Plovanic – Canaccord Genuity Adam Maeder – Piper Richard Newitter – Truist Securities Dev Weerasuriya – Berenberg Capital Markets Operator Good day and welcome to the Inari Medical, Inc. Third Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode.

Inari Medical, Inc. (NARI) Q3 2022 Earnings Call Transcript

IRVINE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2022.

News for Inari Medical Stock (NARI)